Wen Dong Pengfei Lei Xin Liu Qin Li Xiangyang Cheng
10.3389/fimmu.2021.686057
Front Immunol
2021 Nov 4;12:686057.
eml4-alk pd-l1 complete remission lung cancer nivolumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34804000/
Adenocarcinoma of Lung / drug therapy Adenocarcinoma of Lung / genetics Lung Neoplasms / drug therapy Lung Neoplasms / genetics Nivolumab / therapeutic use
Adenocarcinoma of Lung / drug therapy Adenocarcinoma of Lung / genetics Lung Neoplasms / drug therapy Lung Neoplasms / genetics Nivolumab / therapeutic use Case Reports Adenocarcinoma of Lung / pathology Adult Anaplastic Lymphoma Kinase / genetics B7-H1 Antigen / genetics Cell Cycle Proteins / genetics Humans Lung Neoplasms / pathology Male Microtubule-Associated Proteins / genetics Mutation Nivolumab / pharmacology Protein Kinase Inhibitors / therapeutic use Proto-Oncogene Proteins B-raf / genetics Serine Endopeptidases / genetics Treatment Outcome Tumor Microenvironment B7-H1 Antigen Cell Cycle Proteins Microtubule-Associated Proteins Protein Kinase Inhibitors Nivolumab ALK protein, human Anaplastic Lymphoma Kinase BRAF protein, human Proto-Oncogene Proteins B-raf EML4 protein, human Serine Endopeptidases
PMC8600068
34804000
Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
2021